Tuvonralimab Drug Asset Due Diligence Report 2026

This Tuvonralimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Tuvonralimab can convert its Monoclonal antibody profile and CTLA4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tuvonralimab (query alias: Tuvonralimab)
Modality / target	Monoclonal antibody; CTLA4; CTLA4 inhibitors
Highest global status	Phase 2
Originator	Qilu Puget Sound Biotherapeutics Corp.
Active developers	Qilu Pharmaceutical Co., Ltd., Qilu Puget Sound Biotherapeutics Corp.

The MCP disease footprint includes Squamous Cell Carcinoma of Head and Neck, Neoplasms. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600131539	Not Applicable	Not yet recruiting	32	Primary endpoint not disclosed in English source
ChiCTR2600131377	Not Applicable	Not yet recruiting	30	Primary endpoint not disclosed in English source
ChiCTR2600131400	Not Applicable	Not yet recruiting	50	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tuvonralimab addresses Squamous Cell Carcinoma of Head and Neck, Neoplasms. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 63 matched transaction record(s) under the scope “target-level comparable: CTLA4.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CTLA4 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-04-28	China’s BeOne Eyes Global Rights to Huahui Health’s Pre-Clinical Cancer Therapy	Preclinical	US$20.0M upfront; US$1,974.0M milestones
2026-02-22	Harbour BioMed Announces License Agreement and Equity Partnership for a Clinical Stage Antibody	Phase 2	US$50.0M upfront; US$1,100.0M milestones
2026-01-06	Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco	Phase 1/2	US$50.0M upfront; US$2,000.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination of non-viable cells of streptococcus pyogenes and immune checkpoint inhibitor for the treatment of triple negative breast cancer and non-muscle invasive bladder cancer”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition comprising Anti-CTLA4 and Anti-PD1 antibody mixture and therapeutic use thereof”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition comprising mixed antibody of Anti-CTLA4 and Anti-PD1 and therapeutic use thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION